|
Name |
Flavesone
|
Molecular Formula | C14H20O4 | |
IUPAC Name* |
2,2,4,4-tetramethyl-6-(2-methylpropanoyl)cyclohexane-1,3,5-trione
|
|
SMILES |
CC(C)C(=O)C1C(=O)C(C(=O)C(C1=O)(C)C)(C)C
|
|
InChI |
InChI=1S/C14H20O4/c1-7(2)9(15)8-10(16)13(3,4)12(18)14(5,6)11(8)17/h7-8H,1-6H3
|
|
InChIKey |
ZEOCEPNBYPGWGS-UHFFFAOYSA-N
|
|
Synonyms |
Flavesone; 22595-45-5; 9X167ZSG8Z; 6-Isobutyryl-2,2,4,4-tetramethylcyclohexane-1,3,5-trione; 1,3,5-Cyclohexanetrione, 6-isobutyryl-2,2,4,4-tetramethyl-; 1,3,5-Cyclohexanetrione, 2,2,4,4,-tetramethyl-6-(2-methyl-1-oxopropyl)-; UNII-9X167ZSG8Z; FLAVESONE [INCI]; SCHEMBL1573381; DTXSID10177116; Q27273328; 1,3,5-Cyclohexanetrione, 2,2,4,4-tetramethyl-6-(2-methyl-1-oxopropyl)-; 2,2,4,4-TETRAMETHYL-6-(2-METHYLPROPANOYL)CYCLOHEXANE-1,3,5-TRIONE; 2,2,4,4-TETRAMETHYL-6-(2-METHYL-1-OXOPROPYL)-1,3,5-CYCLOHEXANETRIONE
|
|
CAS | 22595-45-5 | |
PubChem CID | 15800949 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 252.31 | ALogp: | 2.7 |
HBD: | 0 | HBA: | 4 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 68.3 | Aromatic Rings: | 1 |
Heavy Atoms: | 18 | QED Weighted: | 0.706 |
Caco-2 Permeability: | -5.354 | MDCK Permeability: | 0.00002350 |
Pgp-inhibitor: | 0.598 | Pgp-substrate: | 0.904 |
Human Intestinal Absorption (HIA): | 0.036 | 20% Bioavailability (F20%): | 0.323 |
30% Bioavailability (F30%): | 0.531 |
Blood-Brain-Barrier Penetration (BBB): | 0.037 | Plasma Protein Binding (PPB): | 71.04% |
Volume Distribution (VD): | 1.022 | Fu: | 35.33% |
CYP1A2-inhibitor: | 0.012 | CYP1A2-substrate: | 0.948 |
CYP2C19-inhibitor: | 0.127 | CYP2C19-substrate: | 0.945 |
CYP2C9-inhibitor: | 0.016 | CYP2C9-substrate: | 0.405 |
CYP2D6-inhibitor: | 0.003 | CYP2D6-substrate: | 0.117 |
CYP3A4-inhibitor: | 0.012 | CYP3A4-substrate: | 0.928 |
Clearance (CL): | 1.568 | Half-life (T1/2): | 0.654 |
hERG Blockers: | 0 | Human Hepatotoxicity (H-HT): | 0.466 |
Drug-inuced Liver Injury (DILI): | 0.976 | AMES Toxicity: | 0.33 |
Rat Oral Acute Toxicity: | 0.175 | Maximum Recommended Daily Dose: | 0.022 |
Skin Sensitization: | 0.431 | Carcinogencity: | 0.558 |
Eye Corrosion: | 0.99 | Eye Irritation: | 0.752 |
Respiratory Toxicity: | 0.906 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003025 | 0.343 | D0R6BR | 0.229 | ||||
ENC002329 | 0.301 | D0A4JK | 0.221 | ||||
ENC002328 | 0.301 | D05TMQ | 0.221 | ||||
ENC001370 | 0.274 | D0W7RJ | 0.219 | ||||
ENC005250 | 0.262 | D01CKY | 0.215 | ||||
ENC002162 | 0.257 | D05BQK | 0.211 | ||||
ENC003284 | 0.252 | D0F0YZ | 0.211 | ||||
ENC002369 | 0.252 | D0U4VT | 0.211 | ||||
ENC003376 | 0.250 | D0H0BG | 0.203 | ||||
ENC004961 | 0.250 | D0H1QY | 0.197 |